A Clinical Trial to Assess the Pharmacokinetics, Safety, and Food Effect of AD-230 in Healthy Adults

ConditionChronic Liver Disease (CLD)

Trial statusNot yet recruiting

Trial phasePhase 1

Trial typeInterventional

Biological sexAll

Age19-64

SponsorAddpharma Inc.

About this trial

A clinical trial to assess the pharmacokinetics, safety, and food effect of AD-230 in healthy adults

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Body mass index (BMI) between 18.5 kg/m2 and 29.9 kg/m2 at the time of screening visit

Subjects aged 19 years or older and under 65 years at the screening visit

Disqualifiers

Participation in another clinical study with an investigational drug within the 6 months from scheduled first administration

Other exclusions applied

Trial design

Design model

Crossover

Treatments tested in this trial

AD-230 (Fasted)
Drug
AD-230 1Tab., Per Oral, Fasted
AD-230 (Fed)
Drug
AD-230 1 Tab., Per Oral, Fed state

Treatment groups

24 Participants

are divided into 2 treatment groups

Group A: Sequence AExperimental treatment 2 interventions

Group B: Sequence BExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

Area under the plasma concentration-time curve during dosing interval (AUCt)

Time frame

-24hours to 72hours

Maximum concentration of drug in plasma (Cmax)

Time frame

-24hours to 72hours

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Addpharma Inc.

Lead sponsor

Source ClinicalTrials.gov

This trial is not recruiting at the moment. You can still explore other options: